October 1, 2019
Axonal Transport and Neurological Disease
May 21, 2019
WE ARE DEVELOPING DRUGS FOR ALZHEIMER’S DISEASE AND PARKINSON’S DISEASE, INCLUDING THE ORPHAN INDICATION DEMENTIA AND ALZHEIMER’S IN DOWN SYNDROME
Our novel approach to addressing chronic and acute neurodegeneration offers new hope in the fight against the largest unmet need of an aging population
Americans with Alzheimer's Disease
Increase in Alzheimer diagnoses by 2060
Failed drug development attempts since 1998
The idea that sticky brain plaques cause Alzheimer’s disease began as an interesting hypothesis and eventually became drug industry dogma. Now, after a string of clinical trial failures, that hypothesis looks less credible than ever.
Raymond J. Tesi STAT News April 30, 2019
Aducanumab's failure puts pressure on field to look beyond amyloid
Ned Pagliarulo March 22, 2019
ALZHEIMER'S DISEASE DRUG FAILURE
Amyloid Plaque and Aβ is NOT The Only Answer
After amyloid failures, it’s time to take a new tack for treating Alzheimer’s
Neurotoxic proteins reduce axonal transport and cause a
Impaired axonal transport lowers levels of neurotransmitters and neurotrophic proteins leading to nerve cell death.
We Are Working to
the Toxic Cascade
Plaques, tangles, and Lewy bodies represent the end stage of neurodegeneration. The disease STARTS with impaired axonal transport caused by high-levels of neurotoxic proteins.
WE ARE DEVELOPING DRUGS FOR ALZHEIMER’S AND PARKINSON’S DISEASE, INCLUDING THE ORPHAN INDICATION DEMENTIA AND ALZHEIMER’S IN DOWN SYNDROME